These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32216086)

  • 1. Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study.
    Jarmusch AK; Vrbanac A; Momper JD; Ma JD; Alhaja M; Liyanage M; Knight R; Dorrestein PC; Tsunoda SM
    Clin Transl Sci; 2020 Sep; 13(5):972-984. PubMed ID: 32216086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
    Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
    Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
    Lammers LA; Achterbergh R; de Vries EM; van Nierop FS; Klümpen HJ; Soeters MR; Boelen A; Romijn JA; Mathôt RA
    Drug Metab Dispos; 2015 Jun; 43(6):819-28. PubMed ID: 25795462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
    Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
    J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19.
    Kaartinen TJK; Tornio A; Tapaninen T; Launiainen T; Isoherranen N; Niemi M; Backman JT
    Clin Pharmacol Ther; 2020 Dec; 108(6):1254-1264. PubMed ID: 32558923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
    Jenkins J; Williams D; Deng Y; Collins DA; Kitchen VS
    Eur J Clin Pharmacol; 2010 Jan; 66(1):67-76. PubMed ID: 19756558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
    Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Ottesen LH; Li Y; Mugundu GM
    Cancer Chemother Pharmacol; 2023 Sep; 92(3):193-203. PubMed ID: 37394627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity.
    Kvitne KE; Åsberg A; Johnson LK; Wegler C; Hertel JK; Artursson P; Karlsson C; Andersson S; Sandbu R; Skovlund E; Christensen H; Jansson-Löfmark R; Hjelmesaeth J; Robertsen I
    Clin Transl Sci; 2022 Nov; 15(11):2685-2696. PubMed ID: 36037309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
    Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
    Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.
    Mohamed MF; Feng T; Enejosa JV; Fisniku O; Othman AA
    J Clin Pharmacol; 2020 Jan; 60(1):86-95. PubMed ID: 31378969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?
    Gazzaz M; Kinzig M; Schaeffeler E; Jübner M; Hsin CH; Li X; Taubert M; Trueck C; Iltgen-Breburda J; Kraus D; Queckenberg C; Stoffel M; Schwab M; Sörgel F; Fuhr U
    Clin Pharmacol Ther; 2018 Dec; 104(6):1249-1259. PubMed ID: 29633238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The initial state of the human gut microbiome determines its reshaping by antibiotics.
    Raymond F; Ouameur AA; Déraspe M; Iqbal N; Gingras H; Dridi B; Leprohon P; Plante PL; Giroux R; Bérubé È; Frenette J; Boudreau DK; Simard JL; Chabot I; Domingo MC; Trottier S; Boissinot M; Huletsky A; Roy PH; Ouellette M; Bergeron MG; Corbeil J
    ISME J; 2016 Mar; 10(3):707-20. PubMed ID: 26359913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.
    Ryu JY; Song IS; Sunwoo YE; Shon JH; Liu KH; Cha IJ; Shin JG
    Clin Pharmacol Ther; 2007 Nov; 82(5):531-40. PubMed ID: 17392720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.
    Elshoff JP; Cawello W; Andreas JO; Braun M
    Clin Pharmacol Drug Dev; 2014 May; 3(3):187-93. PubMed ID: 27128608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
    Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
    Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype.
    Kamiya C; Inui N; Hakamata A; Miyakawa S; Tanaka S; Uchida S; Namiki N; Odagiri K; Watanabe H
    J Pharmacol Sci; 2019 Apr; 139(4):361-366. PubMed ID: 30902567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.
    Kim MG; Kim Y; Jeon JY; Kim DS
    Br J Clin Pharmacol; 2016 Dec; 82(6):1580-1590. PubMed ID: 27495955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
    Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
    Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.